Client of a consultant lobbyist
Incyte Biosciences Canada Corporation
- Meetings this Parliament
- 0
- With MPs
- 0
- Since Nov 2021
- 6
- Active registrations
- 1
Most recent reported meeting: Oct 8, 2024.
Lobbying by Incyte Biosciences Canada Corporation: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
Consultant In effect since May 15, 2024
Consultant David Angus of The Capital Hill Group Inc.
Consultant lobbyists
-
David Angus
Former public office holder
Formerly Caucus Liaison, Prime Minister's Office, House of Commons (1985–1987)
-
David Angus
Former public office holder
Formerly Caucus Liaison, Prime Minister's Office, House of Commons (1985–1987)
Institutions they may lobby: Health Canada (HC), Innovation, Science and Economic Development Canada (ISED), Service Canada (ServCan), Shared Services Canada (SSC), Statistics Canada (StatCan), Transport Canada (TC), Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (2)Hide details
- Incyte would be trying to interface with Innovation, Science and Economic Development Canada (ISED) executives and or associated Federal Departments to discuss: Investing in Canada, Manufacturing in Canada, and Job creation.
- Incyte would be trying to interface with Health Canada (HC) and discuss: Drug Approval and the processes surrounding it, The Patented Medicine Prices Review Board reform, and The Canadian Agency for Drugs and Technologies in Health.
Registration 776466-373202-2. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by David Angus · Consultant
- Daniel McDonald · Director General for Drugs for Rare Diseases, Health Canada (HC)
Incyte would be trying to interface with Innovation, Science and Economic Development Canada (ISED) executives and or associated Federal Departments to discuss: Investing in Canada, Manufacturing in Canada, and Job creation. Read more
Incyte would be trying to interface with Health Canada (HC) and discuss: Drug Approval and the processes surrounding it, The Patented Medicine Prices Review Board reform, and The Canadian Agency for Drugs and Technologies in Health.
-
Reported by David Angus · Consultant
- Eric Costen · Associate Deputy Minister, Health Canada (HC)
Government ProcurementHealth
-
Reported by David Angus · Consultant
- Eric Costen · Associate Deputy Minister, Health Canada (HC)
HealthScience and Technology
-
Reported by David Angus · Consultant
- Eric Costen · Associate Deputy Minister, Health Canada (HC)
HealthScience and Technology
-
Reported by David Angus · Consultant
- Simon Kennedy · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
HealthScience and Technology
-
Reported by David Angus · Consultant
- Simon Kennedy · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
HealthScience and Technology
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.